Davidson-Parker J, Dinsmore W, Khan M H, Hicks D A, Morris C A, Morris D F
Prince of Wales's Hospital, London.
Genitourin Med. 1988 Dec;64(6):383-6. doi: 10.1136/sti.64.6.383.
In a multicentre, prospective, randomised, placebo controlled study of 55 patients with histories of genital warts for at least one year, a four week course of inosine pranobex 3 g a day improved the clinical response to conventional treatment (primarily podophyllin or trichloroacetic (now called trichlorethanoic) acid). Although more patients given inosine pranobex improved than those given placebo, the difference in general response between the two groups was not significant. When other variables (numbers of warts and extent of lesions) were considered, however, the patients given inosine pranobex fared significantly better. These results suggest that inosine pranobex may be worth considering as adjunct to treatment of patients with refractory genital warts.
在一项针对55名有至少一年尖锐湿疣病史患者的多中心、前瞻性、随机、安慰剂对照研究中，为期四周、每日3克的异丙肌苷疗程改善了对传统治疗（主要是鬼臼树脂或三氯乙酸（现称三氯醋酸））的临床反应。虽然接受异丙肌苷治疗的患者比接受安慰剂治疗的患者病情改善更多，但两组总体反应的差异并不显著。然而，当考虑其他变量（疣体数量和病变范围）时，接受异丙肌苷治疗的患者情况明显更好。这些结果表明，异丙肌苷作为难治性尖锐湿疣患者治疗的辅助药物可能值得考虑。
